Gentian has invented a technique that allows measurement of low-concentration markers, and is both rapid and inexpensive. We obtained proof of concept for the technology, and at the moment the corresponding patent is under review. In the current project, we will develop our first prototype immunoassay with our new technology and assess the economic viability of the assay.